Beam Therapeutics (BEAM) has attracted investor attention after recent share price moves, with the stock closing at US$34.55 and showing double digit returns over the past month and over the past three months.

Looking beyond the recent surge, Beam Therapeutics’ 1 month share price return of 26.28% and year to date share price return of 27.30% sit alongside a 1 year total shareholder return of 48.28%. This suggests momentum has recently been building despite weaker 3 and 5 year total shareholder returns.

If Beam’s move has caught your eye, this can be a useful moment to scan the wider biotech space and see which other names are trending in healthcare stocks.

With BEAM’s recent 48.28% 1 year total shareholder return and a current price of US$34.55 against a US$45.20 analyst target, is this genuine value on offer, or is the market already pricing in future growth?

Most Popular Narrative: 77% Undervalued

According to davidlsander, the narrative sets a fair value of US$150 per share, compared to Beam Therapeutics’ last close of US$34.55, creating a wide valuation gap that hinges on the company’s base editing platform and lead clinical programs.

The "Molecular Pencil": Why Beam's Technology is Built to Win. The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool. By creating double-strand DNA breaks, they introduce significant risks, including unpredictable insertions, deletions, and large genomic rearrangements. Beam represents "Gene Editing 2.0". Its base editing platform is a "molecular pencil", a precision instrument that chemically rewrites a single "letter" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors. This thesis is no longer just theoretical. Beam achieved a landmark milestone with BEAM-302, providing the first-ever clinical proof-of-concept for in vivo base editing in humans.

Curious how a high-conviction valuation gets to US$150 per share? The narrative leans on aggressive revenue build out, strong margins and a relatively low discount rate to justify that number.

Result: Fair Value of $150 (UNDERVALUED)

However, this upbeat narrative can be challenged if future trial data underwhelms expectations or if regulatory decisions and partner collaborations do not progress as hoped.

Build Your Own Beam Therapeutics Narrative

If you look at the numbers and come to a different conclusion, or simply want to test your own assumptions, you can quickly build a personalised thesis in just a few minutes with Do it your way.

A great starting point for your Beam Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger watchlist, this is the moment to expand your search and pressure test Beam against other focused opportunities.

• Target potential bargains by scanning these 884 undervalued stocks based on cash flows that might be trading below what their cash flows imply.
• Ride the AI wave by checking out these 25 AI penny stocks that are directly tied to artificial intelligence themes.
• Position yourself early in a fast moving space by reviewing these 79 cryptocurrency and blockchain stocks linked to digital assets and blockchain.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.